Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs
Bullboard Posts
User Avatar Image
(21)
•••
Post by Sinbobon Aug 14, 2012 11:58am
214 Views
Post# 20215316

Eye strain...

Eye strain...

Just got my mail out version for the AGM. It is 1/2 letter sized and you need a magnifyiing glass too read it. Of course this is all very superficial fuff but I must assume certain objective reasons for this tight wad image being sent out to shareholders: R.H. is being extremely judicious in spending our ( and his) money; voting mail outs are becoming extinct so why waste $ on paper; no one really mails in their votes any more; very few read them; R.H. hopes very few will notice much and is trying to fly beneath the radar...setting us up for a dramatic and surprising escalation in the share price; R.H. wants too keep the share price as low as possible to give every chance possible for those close to the scene, and loyal shareholders, every opportunty to buy low before very positive news hits; most unlikely...no one cares anyway.

I've never seen a stock like this. Very disarming and very underexposed. A slow buring fuse?

 

 

Bullboard Posts
Dealroom for high-potential pre-IPO opportunities